VEGFA and breast carcinoma: We therefore hypothesized that 68Ga-TRAP-(RGD)3-PET/CT allows for the in vivo monitoring of αvß3-integrin expression as biomarker of anti-angiogenic therapy effects in orthotopic MDA-MB-231 breast cancer xenografts in mice treated with the VEGF antibody bevacizumab over the course of one week.